Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. Its products include soliqua 100/33/suliqua and adlyxin. The firm focuses on gastrointestinal diseases and metabolic diseases. Its product pipeline includes dasiglucagon, glepaglutide, and dual glucagon product candidates.
